Navigation Links
Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the,Annual Meeting of the Associated Professional Sleep Societies

ROCKVILLE, Md., June 08, 2007 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. announced today that Dr. Tom Roth, Director of the Henry Ford Sleep Disorders and Research Center in Detroit, MI, will deliver an oral presentation on recent Phase III clinical trial results for VEC-162, Vanda's balanced melatonin (MT1/MT2) receptor agonist, at SLEEP 2007, the 21st annual meeting of the Associated Professional Sleep Societies, (APSS).

The Vanda presentation will take place at the Convention Center in Minneapolis, MN on June 13 from 4:00pm - 4:15pm CDT, during the 2:45 - 4:45 pm session entitled, "O31: Pharmacotherapy of Insomnia."

Abstract ID 0773: "Melatonin Agonist VEC-162 Improves Sleep Onset and Maintenance in a Model of Transient Insomnia" (Roth, together with G. Birznieks; C.H. Scott P. Baroldi, M.D., Ph.D.; Mihael H. Polymeropoulos, M.D., Vanda Pharmaceuticals)

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates in clinical development. Vanda's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia and bipolar disorder and has recently completed its Phase III program in schizophrenia. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders which is currently in Phase III for insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness that is in a Phase II clinical trial. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CONTACT: Steven A. Shallcross, Chief Financial Officer of VandaPharmaceuticals Inc., +1-240-599-4500, steven.shallcross@vandapharma.com

Web site: http://www.vandapharma.com//

Ticker Symbol: (NASDAQ-NMS:VNDA)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007 American Psychiatric Association Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
Breaking Medicine Technology:
(Date:4/29/2017)... ... , ... More than half of Americans suffering from noise-induced hearing loss do ... that causes hearing loss? May 1 marks the beginning of Better Hearing & Speech ... well as schedule a hearing evaluation for anyone with concerns about his/her hearing. , ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... (The National Campaign) announces its support for the Access to Contraception for Women ... Shaheen (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure that all ...
(Date:4/28/2017)... ... April 28, 2017 , ... Somnoware, a leading provider of ... which enables sleep physicians to create and edit their interpretation reports. This solution ... a familiar interface that does not require additional training to use. It also ...
(Date:4/28/2017)... ... ... affects much more than energy – it also has mental and physical benefits. According to ... time, which can increase the risk of having a car accident. , This week ... to help you sleep better and feel better:, , Turn off ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
Breaking Medicine News(10 mins):